Cannabis Science Hails The American Medical Association For Urging The United States To Facilitate Clinical Research and Development of Cannabinoid-Based Medicines...

Cannabis Science Hails The American Medical Association For Urging The United States To Facilitate Clinical Research and Development of Cannabinoid-Based Medicines Which Validates The Company’s Strategy To Produce Critically Important FDA Approved Cannabinoid-Based Medicines For Patients

Cannabis Science Inc. (NASD OTCBB: CBIS) an emerging pharmaceutical cannabis company, is hailing the call by the American Medical Association's House of Delegates for “marijuana's status as a federal Schedule I controlled substance be reviewed with the goal of facilitating the conduct of clinical research and development of cannabinoid-based medicines."

Richard Cowan, Cannabis Science CFO, noted, “The AMA has officially joined the other medical groups in their recognition of the medical value of cannabis. Last year, the  American College of Physicians also called for a reclassification of cannabis' Schedule I status. Previously, many other health organizations, including the  American Nurses Association and the  American Public Health Association, have called for the legal recognition of medical cannabis.”

Under federal law, all substances in Schedule I are  defined as possessing "no currently accepted use in treatment in the United States" and also having a high potential for abuse. In 1970 Congress classified marijuana, and all of the cannabinoids (even those with no psychoactive properties) as Schedule I substances upon passage of the Controlled Substances Act. This classification was supposed to be temporary, but blocking research kept it in Schedule I.

Dr. Robert Melamede, PhD., Cannabis Science Inc. President and CEO, stated, “It is now clear that the AMA has embraced the plethora of peer reviewed science supporting the medical applications of the cannabis plant. Their call for the US to facilitate ‘research and development of cannabinoid-based medicines’ is an important validation of our company’s strategy and should make it much easier for us to develop and market products that will help patients. Most people would be shocked to know that the federal government has actually been blocking research on the medical benefits of cannabis while supporting research aimed at demonstrating the negatives. Now that the AMA has embraced this modern science, and President Obama has created new Federal policies and guidelines, the Federal Government can no longer ignore the importance of cannabinoid-based medicines.”

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.